Last reviewed · How we verify

NCT05373160

Reference Values of Different Functional Tests With or Without Cognitive Dual-task in Young Adults

Completed Last updated 13 September 2022
What this trial tests

trial testing Assessment study in Dual-task in 107 participants. Completed in 30 August 2022.

Timeline
25 July 2022
Primary endpoint
25 August 2022
30 August 2022

Quick facts

Lead sponsorIstanbul Bilgi University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment107
Start date25 July 2022
Primary completion25 August 2022
Estimated completion30 August 2022
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Istanbul Bilgi University

Who can join

Adults 18 to 35, any sex, with Dual-task or Functional Test. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this study, reference values for the five basic functional tests that are commonly used, with and without the addition of dual-task activity, will be determined. It will be ensured that healthy normative data that researchers and clinicians can compare in determining the effects in different pathologies by using easy-to-perform evaluations. The aim of this study is to determine the reference values performed with and without dual-task of the five functional tests for young adults according to age and gender by considering the interaction between both mobility and cognitive tasks.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Assessment study

Trials testing the same drug.

Other Istanbul Bilgi University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05373160.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing